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Background: Vaniprevir with P/R improved SVR rates over P/R alone in treatment-experienced patients
with chronic HCV-genotype 1 infection, but treatment failure presents therapeutic challenges.
We identiﬁed RAVs from non-cirrhotic patients failing to achieve SVR on vaniprevir-containing regimens
from a dose/duration-ranging trial of triple-combination therapy.
Methods: Using population analysis, resistance sequencing was performed on all baseline samples and
on samples at virologic failure in the vaniprevir arms. Longitudinal clonal analyses were performed on
viral isolates from six vaniprevir recipients experiencing breakthrough viremia.
Results: Baseline RAVs were detected in two patients subsequently experiencing virologic failure.
At virologic failure, the majority of RAVs had substitutions at R155, A156, or D168. Clonal analyses
identiﬁed novel double/triple variants emerging with continuing vaniprevir dosing.
Conclusions: RAVs were predominantly observed at R155, A156, and/or D168 during virologic failure on
vaniprevir/P/R. Double/triple RAVs were identiﬁed in patients remaining viremic on triple therapy,
suggesting evolution of resistance under selective pressure.
& 2013 Elsevier Inc. All rights reserved.Introduction
Peginterferon-alfa and ribavirin (P/R) had been the standard of
care for chronic hepatitis C virus (HCV) infection until the recent
introduction of direct-acting antiviral agents (Manns et al., 2001;
Fried et al., 2002; Ghany et al., 2011). The two licensed NS3/4A
serine protease inhibitors [boceprevir (VICTRELIS™; Merck,
Whitehouse Station, NJ, USA)] and [telaprevir (INCIVEK™; Vertex
Pharmaceuticals, Cambridge, MA, USA)] when added to P/R
therapy signiﬁcantly improved sustained virologic responsell rights reserved.
HCV, hepatitis C virus;
nal units per milliliter; LLD,
tion; P/R, peginterferon alfa/
ere sponsored and funded
West Point, PA, USA.
.J.O. Barnard),(SVR) rates in previously untreated patients as well as in patients
who had partially responded to or relapsed after a standard course
of P/R alone (Poordad et al., 2011; Jacobson et al., 2011; Sherman
et al., 2011; Bacon et al., 2011; Zeuzem et al., 2011). Accumulating
evidence indicates that even previous null responders have an
appreciable chance at SVR with the newer regimens. However,
virologic failure ultimately occurs in 420% of patients with
genotype 1 HCV infection given triple therapy (Poordad et al.,
2011; Jacobson et al., 2011; Sherman et al., 2011; Bacon et al., 2011;
Zeuzem et al., 2011).
The low ﬁdelity of the HCV RNA-dependent RNA polymerase
coupled with the high rate of virion production gives rise to
a population of genetically related viruses in an infected patient
that harbor minor differences in their RNA genome. As a conse-
quence, it is likely that the majority of single and double-resistant
resistance-associated variants (RAVs) are present prior to treatment
with direct acting antiviral (DAA) agents (Ribeiro et al., 2012). HCV
protease inhibitors are routinely given as part of combination
regimens with P/R in clinical practice (Ghany et al., 2011) or
with other direct-acting antiviral agents in experimental trials.
Fig
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by the emergence of viral variants with resistance to the inhibitor
class, and detectable RAVs can persist up to three years after
cessation of therapy (Sarrazin and Zeuzem 2010; Gambarin-
Gelwan and Jacobson 2012; Welsch and Zeuzem 2012). Accordingly,
the enduring clinical implications of RAVs are not yet fully
understood.
Vaniprevir (MK-7009) is an investigational macrocyclic NS3/4A
protease inhibitor which exhibits potent activity against HCV-
genotype 1. In vitro resistance selection experiments and sequence
data from Phase 1 and 2a clinical studies with vaniprevir have
identiﬁed several viral NS3/4A protease variants associated with
decreased susceptibility to vaniprevir. A recently completed dose/
duration-ranging study (Protocol 009) of vaniprevir combined
with P/R in treatment-experienced patients demonstrated higher
SVR rates than those previously reported with the approved ﬁrst-
generation protease inhibitors combined with P/R (Lawitz et al.,
2012). Using samples from the non-cirrhotic cohort of this Phase
2b trial, the current report examined the types and frequencies of
vaniprevir RAVs detected in viruses isolated from patients rando-
mized to vaniprevir/P/R at baseline and at the time of virologic
failure. Since the technology for HCV population sequencing is
widely available, our results can be directly applied to contempor-
ary clinical practice. In addition, the evolution of resistance was
examined by longitudinal clonal sequence analysis in six patients
that experienced virologic failure with vaniprevir RAVs.Results
Of the 169 treated non-cirrhotic patients in the four vaniprevir
groups (Fig. 1), 73 (43%) had genotype 1a virus, 94 (56%) were infected
with genotype 1b virus and two (1%) patients were infected with a
genotype 1 virus with an indeterminate subtype. A total of 157
vaniprevir recipients (93%) were included in the primary efﬁcacy
analysis: 67 with genotype 1a virus (43%), 88 with genotype 1b virus
(56%), and two (1%) with an indeterminate genotype 1 subtype.
Patient histories of prior P/R failure in the primary efﬁcacy population
encompassed 62 relapses (39%), 42 null responses (26%), 30 partial
responses (19%), and 23 virologic breakthroughs (15%).
Baseline population NS3/4A-sequence data were obtained for
the 155 patients with typeable HCV infections included in the
primary analysis. Seven (5%) patients had viruses that harbored
variants with a decreased resistance to ﬁrst-generation HCV
protease inhibitors, including V36M, T54S, V55A/I/T/V, andWeeks
600 mg bid VAN
+ P/R Follow-up
300 mg bid VAN + P/R 
600 mg bid VAN + P/R 
Placebo + P/R
Placebo + P/R 
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
600 mg bid VAN
+ P/R
240 48
. 1. Dosing arms for MK-7009 P009 Phase 2b trial in treatment-experienced non-cirrhot
th 4 regimens combining vaniprevir with P/R (arms 1–4). The control arm (arm 5) usedR155K (Table 1). NS3/4A genes harboring variants at positions
V36 and T54 confer a o4-fold decrease in sensitivity to MK-7009
in vitro with a cell-based assay. Although variants at these
positions have not been identiﬁed in patients dosed with vanipre-
vir or in replicon resistance selection studies in vitro, these
variants caused a synergistic decrease in sensitivity to vaniprevir
when combined with the R155K variant. Notably two patients who
had been null responders on their previous P/R regimen harbored
R155K variants in combination with either V36M or T54S at
baseline, both of whom experienced virologic failure on vanipre-
vir/P/R; one patient had a null response and the other had
breakthrough viremia.
Population resistance analyses revealed that the majority of
emergent RAVs had amino acid substitutions at positions R155,
A156, or D168 (Table 2), all of which conferred decreased vani-
previr susceptibility relative to the reference strains (Table 3).
Of the 28 patients who experienced virologic failure in the
vaniprevir-dosing arms of this study, resistance data were avail-
able at virologic failure for 26 patients. The NS3/4a gene could not
be ampliﬁed from samples obtained at virologic failure from the
remaining two patients. Of the 26 patients with resistance data at
virologic failure, 17 had genotype 1a virus and 9 had genotype 1b
virus. RAVs were detected in 17 of 17 (100%) genotype 1a
infections and 9 of 9 (100%) genotype 1b infections. The most
frequently detected protease variants associated with virologic
failure among genotype 1a infected patients were at positions
R155, A156, and D168, whereas the most commonly detected
protease variants among patients with genotype 1b infections
were at positions D168 and A156. Similar to other studies with
ﬁrst-generation HCV proteases, R155K was only found by popula-
tion sequencing in genotype 1a.
All 26 patients included in the primary efﬁcacy analysis whose
HCV isolate was sequenced at the time of virologic failure had
RAVs (Table 4). Of these 26 vaniprevir recipients experiencing
virologic failure with sequence data, 12 had virologic break-
through, 1 had a null response, 2 had partial responses, and
11 had relapses. In the 12 patients who experienced virologic
breakthrough, variants were detected at positions R155K, A156,
and D168. Compared to patients with relapse, partial response, or
null response, patients with breakthrough more often had RAVs
detected at more than one locus. RAVs were detected at multiple
loci (R155/D168, R155/A156, or A156/D168) in 5/12 breakthrough
patients, while the remainder had variants at only R155 or D168
detected. Of the 11 relapse patients, only one had RAVs detected at
more than one locus (R155K and D168V). The remaining patientsFollow-up
Follow-up
Follow-up
Follow-up
n=38
n=39
n=39
n=41
n=42
71.1%
84.6%
66.7%
78.0%
19.0%
SVR
Rate
Evaluable
Patients
72
ic patients. After stratiﬁcation by type of previous failure, patients were treated
PR alone.
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with a null response had RAVs detected at R155K while the two
patients with partial responses had D168T detected at virologic
failure. Other than the presence of RAVs at more than one locus in
breakthrough patients, there was no speciﬁc variant associated
with a particular type of treatment failure.
By design, stopping rules for futility were not stipulated until
week 12. Therefore, patients were kept on vaniprevir or placebo
and P/R therapy until week 12 of the study irrespective of their
virologic response during this period. In order to characterize theTable 2
Summary of emergent HCV-protease variants during or after vaniprevir regimens.
Vaniprevir dosing
arm
N in primary
analysisa
N failed N with VF N with
sequence data
Arm 1 V600/P/
R24 wk
38 11 9 8
Arm 2 V600/P/
R24 wk+P/
R24 wk
39 6 3 3
Arm 3 V300/P/
R48 wk
39 13 11 10
Arm 4 V600/P/
R48 wk
41 9 5 5
N, number of non-cirrhotic patients in the designated category; V, vaniprevir; P, pegint
Variants detected at baseline are not tabulated here. No RAVs were identiﬁed in patien
a These counts do not include patients discontinued for administrative reasons who
b The two viral breakthroughs in Arm 2 occurred within the ﬁrst 24 weeks of treat
Table 1
Summary of HCV-protease variants detected at baseline by population sequencing
from vaniprevir recipients according to HCV genotype.
NS3/4A Protease variantsa Genotype 1A
(N¼73 patients)
Genotype 1B
(N¼94 patients)
V36M 2 None
T54S 1 2
V55A 3 None
V55I 2 None
T54S, V55I 1 1
V36M/L, T54T/S, V55T/I/A/V 1 None
T54S/R155Kb 1 None
V36M/R155Kb 1 None
a 167 of the 169 baseline isolates were typeable and are listed here.
b Only these 2 variants which included R155K exhibited phenotypic resistance
to vaniprevir. Both patients with genotype 1A HCV harboring R155K variants
experienced virologic failure.evolution of RAVs in patients under these circumstances, long-
itudinal clonal analysis was performed on six patients with break-
through viremia (4 with genotype 1a virus and 2 with genotype 1b
virus) who had variants detected at positions R155 or D168 at
virologic failure by population sequencing. In this analysis, 40–80
clones were sequenced at each time point, allowing linkage of any
double/triple variants to be established.
In all patients, clonal analyses revealed that the overwhelming
majority of viruses in each patient sequenced at virologic failure
harbored vaniprevir RAVs indicating that wild-type viruses were
suppressed during vaniprevir/P/R dosing (Fig. 2). In addition, the
number of RAVs detected after virologic failure increased during
continued vaniprevir/P/R dosing so that double/triple RAVs were
detected more frequently in most patients at later time points.
In 2/6 genotype 1b patients, single RAVs were observed at position
D168 at virologic failure. However, in one patient, double RAVs
were observed at positions R155 and D168 20 days after virologic
failure, during vaniprevir/P/R dosing. This pattern of increasing
RAV frequency and the selection of double-RAV viruses was
observed in all genotypes 1a and 1b infected patients during the
vaniprevir/P/R dosing period after virologic failure. The number of
double/triple RAVs declined after discontinuation of therapy.Discussion
The parent Phase II study evaluated four treatment regimens
combining vaniprevir with P/R compared to 48 weeks of PR aloneN with RAV HCV genotype Category of
virologic failure
RAVs detected by
population
sequencing
8 1A Breakthrough R155K, D168F/N/T/A/
Y/S
1A Breakthrough R155K, D168Y
1A Relapse D168V
1A Relapse D168V
1A Relapse D168H
1A Relapse R155K, D168V
1A Relapse R155K
1B Relapse D168T
3 1A Null response R155K
1B Breakthroughb A156G, D168T
1B Breakthroughb D168T
10 1A Breakthrough R155K
1A Breakthrough R155K
1A Breakthrough D168T
1B Breakthrough D168 Y,V
1B Breakthrough D168E
1B Breakthrough D168V,Y,F
1A Relapse R155K
1A Relapse R155K
1A Relapse R155K
1B Partial responder D168T
5 1A Breakthrough R155K, A156S
1A Breakthrough R155K, D168N
1B Partial Response D168T
1A Relapse R155K
1B Relapse D168A
erferon alpha; R, ribavirin; VF, virologic failure.
ts dosed with PR alone.
had undetectable viral loads at the last visit on record.
ment while the patients were still receiving vaniprevir.
Table 3
In vitro phenotypic data for RAVs using a secreted alkaline phosphatase assay.
Genotype Variant IC50 (nM) Fold-change in IC50
1a Wild type (H77) 7.97 N/A
V36A 15.33 1.9
V36M 28.87 3.6
V36M/R155K 4589 575.8
T54A 19.96 2.5
T54S 13.17 1.7
T54S/R155K 2341 293.7
R155K 342 42.9
R155K/A156S 6589 826.7
A156S 52.03 6.5
A156T 210.4 26.4
A156V 1151 144.4
D168A 746.2 93.6
D168E 98.88 12.4
D168F 6753 847.3
D168H 1053 132.1
D168N 159.5 20.0
D168T 4397 551.7
D168V 1485 186.3
D168Y 1244 156.1
1b Wild type (Con1) 6.803 N/A
V36A 4.213 0.6
V36M 14.92 2.2
T54A 4.69 0.7
T54S 1.463 0.2
T54S/R155K 2698 396.6
R155K 445.5 65.5
R155Q 575.2 84.6
R155Q/D168N 4447 653.7
A156T 403.6 59.3
A156V 550.9 81.0
A156S 19.51 2.9
D168N 200.5 29.5
D168A 1353 198.9
D168E 141.7 20.8
D168F 7621 1120.2
D168H 529.9 77.9
D168T 4911 721.9
D168V 451.4 66.4
D168Y 1899 279.1
Table 4
Association of the type of prior virologic failure with the development of vaniprevir
resistance.
Virologic failure on
vaniprevir regimen
Prior treatment failure on P/R therapy
Null
response
Partial
response
Breakthrough Relapse Total
Null response 1 0 0 0 1
Partial response 2 0 0 0 2
Breakthrough 6 3 3 0 12
Relapse 6 2 2 1 11
Total 15 5 5 1 26
The table shows data for all 26 patients with sequence data at the time of virologic
failure, all of whom harbored RAVs. For technical reasons, sequencing could not be
completed on viral isolates from two additional patients (one prior null responder
and one prior partial responder).
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2012). Patients retreated with vaniprevir in addition to P/R
achieved signiﬁcantly higher SVR rates than patients receiving
another course of P/R without a third drug. Importantly, no
patients had received a direct-acting antiviral agent for HCV prior
to entry.
Resistance-associated amino acid variants were predominantly
observed at positions R155, A156, and/or D168 in patients failing
to achieve SVR by population sequencing. More genotype 1ainfected patients experienced virologic failure (17/67, 25%) com-
pared to genotype 1b infected patients (9/88, 10%). As has been
observed with other HCV protease inhibitors, R155K was seen
exclusively in genotype 1a by population sequencing, likely due
to the higher number of nucleotide changes required to generate
the R155K RAV in genotype 1b viruses (Cento et al., 2012).
However, R155Q and R155N viruses were observed by clonal
sequencing in one genotype 1b patient in combination with
D168N or T, respectively. In genotype 1b, R155Q and N require
only a single change from the consensus sequence. As double-
variants only were observed after virologic failure and resulted in
a synergistic decrease in susceptibility to vaniprevir in vitro, it is
possible that these double-variants have a selective advantage
over the single variants during vaniprevir dosing.
Overall, 5/12 patients that experienced virologic breakthrough
while on vaniprevir had RAVs detected at more than one locus in
the NS3 region. As these patients all experienced virologic failure
during the dosing period, it is likely that the detection of RAVs at
more than one locus represents the selection and expansion of
multiple variants that have a selective advantage in the presence
of vaniprevir. By comparison, all but one of the 11 patients
relapsing after cessation of vaniprevir dosing had RAVs detected
at a single vaniprevir RAV locus. As viruses isolated at relapse are
not under ongoing vaniprevir selective pressure, it is likely that the
RAVs identiﬁed in these patients represent variants selected
during vaniprevir dosing that were not cleared by vaniprevir/P/R
therapy and are able to cause virologic failure after dosing.
In a small sample of six patients with virologic breakthrough,
clonal analyses were performed to assess the evolution of resis-
tance during continued vaniprevir/P/R dosing to Week 12 of the
study. In the majority of patients, additional novel double and
triple variants were identiﬁed prior to cessation of vaniprevir
dosing at Week 12 of the study, indicating continued evolution of
resistant viruses during failing therapy. Double-RAVs exhibited
larger decreases in susceptibility to vaniprevir compared to single
RAVs. Selection of double-and triple RAVs during therapy may be
indicative of increased viral ﬁtness in the face of vaniprevir
selective pressure (Kieffer et al., 2007; Sarrazin et al., 2007).
In all cases, the frequencies of RAVs declined following the
cessation of vaniprevir/P/R therapy. However, some double-
variants did persist for over 100 days.
R155K variants were present in two patients prior to treatment
despite never having been exposed to a HCV-protease inhibitor
(Kieffer et al., 2007; Bartels et al., 2013). Both cases with baseline
RAVs were followed by virologic failure on vaniprevir/P/R.
Both patients were prior P/R null-responders, perhaps indicating
that patients with a combination of pre-existing vaniprevir RAVs
and a history of poor interferon responsiveness might be less likely
to respond to a vaniprevir/P/R regimen. However, due to the small
number of patients with baseline protease RAVs identiﬁed so far,
Bartels et al., 2013. Vallet et al. (2011), Vicenti et al. (2012) the
utility of baseline resistance testing requires further study as the
use of directly-acting antiviral agents for chronic HCV infection
becomes increasingly commonplace.
The presence of R155K variants may be of particular prognostic
signiﬁcance. Perhaps, as with initiation or change in antiretroviral
regimens for HIV-infected patients, upfront resistance testing
may eventually become part of the standard of care, particularly
for patients exposed to protease-inhibitors during earlier treat-
ment regimens. The lower resistance barrier of subtype 1a may
make resistance sequencing more informative in infections with
subtype 1a than in subtype 1b infections (Cento et al., 2012).
However, unlike the HIV paradigm where resistant virus is
archived indeﬁnitely, the implications of the emergence of RAVs
during treatment for HCV remain much less clear (Welsch and
Zeuzem 2012).
Fig. 2. Longitudinal clonal analysis for the 6 studied patients with breakthrough viremia on vaniprevir/P/R. The infecting HCV subtype, the patient IL28B genotype, and the
assigned treatment regimen are shown for panel A–F. Note that the time on study given on the x-axes is not always on the same scale for each graph.
R.J.O. Barnard et al. / Virology 443 (2013) 278–284282
R.J.O. Barnard et al. / Virology 443 (2013) 278–284 283In the pivotal boceprevir studies that used a 4-week lead-in
period with P/R before addition of boceprevir, lack of interferon
responsiveness (o1-log drop in HCV RNA levels by Week 4) was
associated with a high rate of failure accompanied by the emer-
gence of RAVs. In the current vaniprevir trial, no lead-in period
with P/R alone was used; consequently, our data can only infer
whether a poor historical response to interferon predicts vanipre-
vir failure and resistance. Among the 44 previous null responders
in the primary efﬁcacy analysis that received vaniprevir, there
were 18 virologic failures, of whom 17 were sequenced; all 17 had
RAVs by population sequencing. A null response to prior P/R
therapy may represent the historical counterpart of interferon
non-responsiveness during the lead-in phase in the pivotal boce-
previr trials (Poordad et al., 2011; Bacon et al., 2011), predicting
virologic failure with the emergence of RAVs when a single DAA is
added to P/R for retreatment.
Early treatment discontinuation can help avoid unnecessarily
prolonged therapy with its attendant toxicity and additional
costs in patients who are very unlikely to achieve SVR. Early
discontinuation is also likely to decrease the complexity and
frequency of RAVs selected by a suboptimal or failing regimen.
With regimens containing a protease inhibitor along with P/R,
stopping rules serve to preempt the emergence of RAVs in patients
destined to fail. Consequently, stopping rules for futility have been
developed for the licensed protease inhibitors (Jacobson et al.,
2012; Adda et al., 2013). To preempt the selection of RAVs as well
as minimize unnecessary cost and toxicity, DAA-based regimens
should be discontinued promptly anytime virologic failure
becomes evident through frequent monitoring of HCV-RNA levels
during treatment.Methods
Objective
An analysis of RAVs present at baseline or emerging during
vaniprevir combination therapy was performed by population and
selective clonal sequencing of the viral NS3/4A protease to
determine the resistance patterns selected in patients not achieving
SVR during a Phase 2b dose/duration-ranging study in P/R-experi-
enced patients with HCV-genotype 1 infection.
Study design
The parent study was a randomized, active-control, double-
blind study performed in non-cirrhotic patients with chronic
hepatitis C-genotype 1 infection who had previously failed P/R
alone in order to assess the efﬁcacy of 4 dosing regimens of
vaniprevir given with standard weight-based doses of P/R relative
to P/R without a protease inhibitor (Lawitz et al., 2012).
The primary efﬁcacy outcome was the SVR rate assessed by the
proportion of patients achieving undetectable HCV-RNA levels
24 weeks after discontinuation of all study medications. The
protocol was approved by the appropriate institutional review
boards and regulatory agencies, and written informed consent was
obtained before any patient was enrolled. The conduct of the trial
followed the principles of Good Clinical Practice.
Patients 18 to 65 years of age with hepatitis C-genotype 1
infection who had failed prior treatment with standard P/R therapy
were eligible for MK-7009 Protocol 009 if their screening HCV RNA
level was ≥4105 IU/mL. Null responders to prior P/R treatment
were to be limited to ∼25% of the non-cirrhotic patients enrolled in
the trial. Exclusion criteria included HIV co-infection, evidence of
cirrhosis by liver biopsy or noninvasive assessment, decompensated
liver disease, or any condition contraindicating retreatment with P/R. Upon entry, patients were stratiﬁed on the basis of their prior
response to P/R as null response, partial response, breakthrough on
therapy, and relapse after completing treatment. Vaniprevir was
administered in combination with P/R in 4 dosing regimens; the
control group received P/R plus placebo (Fig. 1). Patients treated
with ≥1 dose of vaniprevir served as the primary population for the
efﬁcacy analysis.
Specimens were obtained from all patients at baseline for
population sequencing of the HCV NS3/4A protease, which was
to be repeated on the ﬁrst sample qualifying as virologic failure
per protocol. Failure to achieve SVR was operationally deﬁned as
o2-log decline in baseline HCV RNA level by Week 12 (null
response), quantiﬁable HCV RNA levels at Week 24 or persistently
detectable but unquantiﬁable HCV RNA levels at Weeks 24 and 28
(partial response); a log-increase from nadir HCV-RNA level by
Week 12 or a HCV RNA level 4100 IU/mL during therapy after
becoming undetectable (breakthrough); or detectable HCV RNA
following discontinuation of all study treatment after being
undetectable at the end of treatment (relapse). A convenience
sample selected from patients with breakthrough viremia while
on vaniprevir underwent clonal sequencing analysis.Viral and resistance assays
HCV RNA levels were measured by COBAS TaqMan assay (Roche
Diagnostics, Branchburg, NJ, USA), which has a lower limit of
detection (LLD) of 10 IU/mL and a lower limit of quantiﬁcation
(LLQ) of 25 IU/mL. Potential viral resistance was identiﬁed by
population sequencing of NS3/4A gene. DNA amplicons obtained
at baseline and at the time of virologic failure were puriﬁed and
subjected to DNA-sequence analysis. Because of technical assay
limitations (such as ampliﬁcation sensitivity and the potential for
founder effects at lower viral loads), population sequencing was
only performed on samples with 41000 HCV RNA IU/mL. For the
population analysis, HCV RNA was puriﬁed from patient plasma
samples using the QIAamps viral RNA puriﬁcation kit (Qiagen,
USA) according to the manufacturer's instructions. NS3/4a HCV
cDNA was generated using SuperScript III reverse transcriptase
(Invitrogen, USA) and eight independent PCR ampliﬁcations gen-
erated by nested PCR. Between 1 and 4 PCR products were
sequenced at each time point using standard methods and the
resultant amino acid sequences aligned to HCV genotype 1a (H77)
or 1b (Con1) reference sequences. Clonal analyses were done
longitudinally on a convenience subset of 6 vaniprevir recipients
experiencing virologic breakthrough as deﬁned per protocol by
Monogram Biosciences (Monogram Biosciences, South San
Francisco, CA, USA) or at the Merck Research Laboratories (West
Point, PA, USA). For clonal sequencing, PCR ampliﬁcation was
performed on the NS3 region only and the resultant amplicons
cloned into a TOPO TA vector (Invitrogen). Up to 80 clones were
sequenced for each time point. IC50 of vaniprevir was measured for
viruses harboring protease variants in a cell-based HCV protease
assay using a secreted alkaline phosphatase assay to determine
whether the genetic variant conferred phenotypic resistance
(Ludmerer et al., 2008).Disclosures
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